Bowen Hanes & Co. Inc. Has $1.78 Million Stake in Zoetis Inc. $ZTS

Bowen Hanes & Co. Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 50.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 14,166 shares of the company’s stock after selling 14,270 shares during the period. Bowen Hanes & Co. Inc.’s holdings in Zoetis were worth $1,782,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Nordea Investment Management AB increased its stake in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd increased its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after acquiring an additional 935,432 shares during the last quarter. Prudential PLC increased its stake in shares of Zoetis by 17.7% in the third quarter. Prudential PLC now owns 197,852 shares of the company’s stock worth $28,950,000 after acquiring an additional 29,702 shares during the last quarter. Finally, AE Wealth Management LLC increased its stake in shares of Zoetis by 71.3% in the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock worth $18,185,000 after acquiring an additional 60,167 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 1.5%

Shares of ZTS opened at $77.51 on Thursday. The company has a 50-day simple moving average of $101.99 and a 200-day simple moving average of $116.09. The firm has a market capitalization of $32.49 billion, a P/E ratio of 12.85, a P/E/G ratio of 1.25 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $171.52.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s payout ratio is presently 35.16%.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. Citigroup decreased their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. UBS Group decreased their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $133.92.

Insider Activity at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 over the last quarter. 0.22% of the stock is owned by company insiders.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Some market commentary says Zoetis could still be a value opportunity, with one analysis describing the stock as a potential deep-value play with significant upside if the business stabilizes.
• Neutral Sentiment: Zoetis presented at the William Blair Growth Stock Conference, but no major new operating update from that event was highlighted in the headlines provided.
• Negative Sentiment: Multiple law firms announced or reminded investors about a class-action lawsuit alleging securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, with several notices urging shareholders to seek lead-plaintiff status by July 27, 2026. These repeated legal alerts can weigh on the stock. Article Title
• Negative Sentiment: One article said Zoetis has underperformed its industry peers over the past year, reinforcing concerns about recent relative stock performance.
• Negative Sentiment: Investor notices from Robbins Geller, Levi & Korsinsky, the Schall Law Firm, Howard G. Smith, Bernstein Liebhard, The Gross Law Firm, DJS Law Group, and others all highlighted the ongoing lawsuit, increasing headline risk for ZTS.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.